Cardiome Pharma Corp. Company Profile (NASDAQ:CRME)

Analyst Ratings

Consensus Ratings for Cardiome Pharma Corp. (NASDAQ:CRME) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $10.12 (223.32% upside)

Analysts' Ratings History for Cardiome Pharma Corp. (NASDAQ:CRME)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016HC WainwrightInitiated CoverageBuy$9.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016MackieUpgradeHold -> Speculative Buy$5.20 -> $8.60View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/13/2016Canaccord GenuityReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015LB SecuritiesReiterated RatingBuy$12.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2014Laurentian Bank of CanadaInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Cardiome Pharma Corp. (NASDAQ:CRME)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/13/2016Q116($0.21)($0.06)$6.34 million$7.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.19)($0.37)$7.74 million$4.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2015Q315($0.23)($0.31)$7.08 million$5.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.25)($0.43)$7.67 million$5.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q115($0.28)($0.23)$7.48 million$5.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.14)($0.39)$8.54 million$7.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.13)($0.26)$6.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.16)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.11)($0.20)$8.08 million$7.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($0.22)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q3 13($0.21)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2013Q2 13($0.19)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2013Q113$1.48$1.47$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2013Q412($0.05)$0.13$0.84 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q312($0.11)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2011($0.10)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/16/2011($0.11)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2011($0.08)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cardiome Pharma Corp. (NASDAQ:CRME)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.14)($0.13)($0.14)
Q2 20161($0.24)($0.24)($0.24)
Q3 20161($0.25)($0.25)($0.25)
Q4 20161($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cardiome Pharma Corp. (NASDAQ:CRME)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cardiome Pharma Corp. (NASDAQ:CRME)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Cardiome Pharma Corp. (NASDAQ:CRME)
DateHeadline
07/29/16 07:16 AMCardiome Pharma Corporation (CRME) Updated Price Targets - FTSE News
07/28/16 10:45 AMCardiome Pharma Corp (NASDAQ:CRME) Plunge Following Dilution Plans - HotStocked
07/28/16 10:45 AMCardiome Pharma Corp. (NASDAQ:CRME) Unveils $30M Underwritten Public Offering - Journal Transcript
07/27/16 03:28 PMCardiome Pharma : Announces Pricing of Public Offering of 10,000,000 Common Shares
07/27/16 03:04 PMNew York Community Bank Drops in on Wednesday’s 52-Week Low Club -
07/27/16 11:22 AMMid-Afternoon Market Update: Crude Oil Drops Below $43; Linear Technology Shares Spike Higher - Nasdaq
07/26/16 11:37 AMCardiome Pharma (CRME) Announces Common Stock Offering - StreetInsider.com
07/26/16 11:37 AMBiotech Movers: Gilead Sciences, Inc. (NASDAQ:GILD) and CARDIOME PHARMA CORP(NASDAQ:CRME) - Market Exclusive
07/26/16 11:37 AMPre-Market Investor's Alert: CARDIOME PHARMA CORP. (NASDAQ:CRME), Special Opportunities Fund Inc. (NYSE:SPE) - Review Fortune
07/25/16 08:10 PMCardiome Pharma : Announces Proposed Public Offering of Common Shares
07/20/16 09:50 AMCardiome Pharma Corporation Ord (NASDAQ:CRME) Short Interest Decreased By 4.42% - Consumer Eagle
07/19/16 03:29 PMHow Analysts Rated CARDIOME PHARMA CORP (NASDAQ:CRME) Last Week? - Press Telegraph
07/15/16 09:02 AMBroker Outlook For Cardiome Pharma Corporation (CRME) - Fiscal Standard
07/14/16 07:19 AMCardiome Pharma's (CRME) ESMOCARD and ESMOCARD LYO Approved in Italy - StreetInsider.com
07/14/16 07:19 AMCardiome Pharma Corporation Ord (NASDAQ:CRME) Sellers Increased By 27.09% Their Shorts - Press Telegraph
07/14/16 07:19 AMCardiome Pharma Corp (NASDAQ:CRME) Institutional Investors Quarterly Sentiment - Consumer Eagle
07/14/16 07:00 AMESMOCARD® and ESMOCARD LYO® receive pricing approval and reimbursement in Italy - [CNW Group] - ESMOCARD® and ESMOCARD LYO® receive pricing approval and reimbursement in Italy
07/10/16 03:14 PMCardiome Pharma Corporation Ord (NASDAQ:CRME) Short Interest Increased By 27.09% - Engelwood Daily
07/04/16 08:15 AMNYSE, NASDAQ Most Advanced Stocks, July 1
06/30/16 09:58 AMCardiome Pharma Corporation Ord (NASDAQ:CRME) Short Interest Increased By 27.09% - Press Telegraph
06/25/16 07:17 AMWere Analysts Bearish CARDIOME PHARMA CORP (NASDAQ:CRME) This Week? - Engelwood Daily
06/23/16 02:16 PMCardiome Pharma Corporation (CRME) Current Analyst Ratings - Fiscal Standard
06/09/16 09:27 PMCardiome Pharma Corp. (NASDAQ:CRME) Upcoming Earnings: What matter for investors? - iStreetWire
06/08/16 11:35 AMH.C. Wainwright Initiates Coverage on CARDIOME PHARMA CORP to Buy - Trade Calls
06/05/16 11:09 AMAfter Last Week What Do Analysts Think Of Cardiome Pharma Corporation (CRME) - Share Trading News
06/03/16 09:34 PMCardiome Pharma Corporation (NASDAQ:CRME) Stock Update & Estimates - Stock Tick Tock
06/03/16 11:33 AMCardiome Pharma Corporation (NASDAQ:CRME) Set To Release Quarterly Earnings - Investor Newswire
06/02/16 09:27 PMShare Rating Focus on Cardiome Pharma Corporation (NASDAQ:CRME) - HNN - Share Rating Focus on Cardiome Pharma Corporation (NASDAQ:CRME)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.77 on shares of Cardiome Pharma Corporation (NASDAQ:CRME). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research.and more »
06/01/16 09:33 PMTarget Price and Stock Performance Rundown for Cardiome Pharma Corporation (NASDAQ:CRME) - HNN - Target Price and Stock Performance Rundown for Cardiome Pharma Corporation (NASDAQ:CRME)HNNDuring the latest trading session, Cardiome Pharma Corporation (NASDAQ:CRME) shares traded +3.21%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been ...and more »
06/01/16 10:51 AMHC Wainwright Begins Coverage on Cardiome Pharma Corp (CRME) - Let Me Know About This - HC Wainwright Begins Coverage on Cardiome Pharma Corp (CRME)Let Me Know About ThisCardiome Pharma Corp logo Analysts at HC Wainwright initiated coverage on shares of Cardiome Pharma Corp (NASDAQ:CRME) in a research note issued to investors on Wednesday. The firm set a “buy” rating and a $9.50 price target on the ...Cardiome Pharma Corporation (NASDAQ:CRME) Hit With "Buy" Rating At H.C. Wainwright, Firm Sees $9.50 Stock PriceFranklin Independentall 5 news articles »
06/01/16 06:28 AMCoverage initiated on Cardiome Pharma by H.C. Wainwright -
05/31/16 03:29 PMRecent Investment Analysts' Ratings Changes for Cardiome Pharma Corp (CRME) - Let Me Know About This - Recent Investment Analysts' Ratings Changes for Cardiome Pharma Corp (CRME)Let Me Know About ThisShares of Cardiome Pharma Corp (NASDAQ:CRME) opened at 4.82 on Tuesday. Cardiome Pharma Corp has a 1-year low of $3.70 and a 1-year high of $10.40. The company has a 50-day moving average of $4.72 and a 200-day moving average of $5.98.
05/27/16 11:57 AMStock Rating Review for Cardiome Pharma Corporation (NASDAQ:CRME) - Wall Street Hints and News - Stock Rating Review for Cardiome Pharma Corporation (NASDAQ:CRME)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1.77 on shares of Cardiome Pharma Corporation (NASDAQ:CRME). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research.and more »
05/26/16 11:03 AMTarget Check and Stock Performance Recap Cardiome Pharma Corporation (NASDAQ:CRME) - Wall Street Hints and News - Target Check and Stock Performance Recap Cardiome Pharma Corporation (NASDAQ:CRME)Wall Street Hints and NewsIn recent session activity, Cardiome Pharma Corporation (NASDAQ:CRME) shares have traded -0.21%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has been ...and more »
05/23/16 12:23 PMCardiome Pharma Corp. :CRME-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
05/23/16 07:25 AMCardiome Pharma (CRME) Jumps: Stock Moves 8.1% Higher -
05/22/16 09:43 PMCardiome Pharma Corporation (CRME) Broker Price Targets For The Coming Week - Share Trading News - Cardiome Pharma Corporation (CRME) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Cardiome Pharma Corporation (CRME). The latest reports which are currently in issue on Sunday 22nd of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...Were Analysts Bullish CARDIOME PHARMA CORP (NASDAQ:CRME) This Week?The PostAfter Today's Huge Increase, Is CARDIOME PHARMA CORP's Near-Term Analysis Positive?Franklin Independentall 3 news articles »
05/20/16 11:06 AMAnalyst Rating Check on Cardiome Pharma Corporation (NASDAQ:CRME) - Wall Street Hints and News - Analyst Rating Check on Cardiome Pharma Corporation (NASDAQ:CRME)Wall Street Hints and NewsCurrently, sell-side analysts have provided a consensus stock rating of 1.77 on shares of Cardiome Pharma Corporation (NASDAQ:CRME). Analysts that cover the company will usually offer Buy, Sell, or Hold recommendations based on in-depth research.and more »
05/20/16 11:06 AMRevenue Update on CARDIOME PHARMA CORP(NASDAQ:CRME) - Trade Calls - Revenue Update on CARDIOME PHARMA CORP(NASDAQ:CRME)Trade CallsCARDIOME PHARMA CORP(NASDAQ:CRME) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 13, 2016. Company reported revenue of $7.09M. Analysts estimated a revenue of $6.35M. Earnings ...Latest Analyst Ratings For Cardiome Pharma Corporation (CRME)Share Trading Newsall 2 news articles »
05/19/16 10:01 PMShare Performance and Target Price Review for Cardiome Pharma Corporation (NASDAQ:CRME) - Wall Street Hints and News - Share Performance and Target Price Review for Cardiome Pharma Corporation (NASDAQ:CRME)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Cardiome Pharma Corporation ...and more »
05/18/16 11:38 AMBroker Outlook For Cardiome Pharma Corporation (CRME) - Share Trading News - Broker Outlook For Cardiome Pharma Corporation (CRME)Share Trading News(Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, ...
05/16/16 09:25 PMCardiome Pharma Corporation (NASDAQ:CRME) Quarterly EPS Projection At $-0.23 - Investor Newswire - Cardiome Pharma Corporation (NASDAQ:CRME) Quarterly EPS Projection At $-0.23Investor NewswireA week earlier, the EPS projection was $-0.23 while 30-days ago it was $-0.23. This target was set at $-0.23 60 days ago and it was $-0.23 90 days earlier. From a week ago, the change in estimates is 0%. EPS was revised 0 times up and 0 down in last ...
05/15/16 02:24 AMCardiome Pharma's (CRME) CEO Bill Hunter on Q1 2016 Results - Earnings Call Transcript - Welcome to the Cardiome’s 2016 First Quarter Financial Results Conference ... not something every specialty pharma company can say, particularly over the last eight months or so and particularly as we face an uncertain election in the United States.
05/13/16 08:58 AMCardiome Reports First Quarter 2016 Financial Results - [at noodls] - VANCOUVER, May 13, 2016 - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for its first quarter ended March 31, 2016. Amounts, unless specified otherwise, are expressed ...
05/13/16 06:11 AMCardiome reports 1Q loss -
05/13/16 05:19 AMPerformance Recap and Target Perspective on Cardiome Pharma Corporation (NASDAQ:CRME) - Wall Street Hints and News - Performance Recap and Target Perspective on Cardiome Pharma Corporation (NASDAQ:CRME)Wall Street Hints and NewsIn the latest trading session, shares of Cardiome Pharma Corporation (NASDAQ:CRME) moved -0.20%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check, ...and more »
05/12/16 02:27 PMCardiome Announces the Launch of ESMOCARD Solution for Injection in France - [at noodls] - Vancouver, Canada, May 12, 2016 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that ESMOCARD (esmolol hydrochloride) 100mg/10ml solution for injection has been commercialized by its ...
05/12/16 05:29 AMCardiome Pharma Corporation: Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13 - Vancouver, Canada, May 11, 2016-- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the first quarter ended March 31, 2016 on the morning of Friday, May 13, 2016. Cardiome will hold a conference call ...
05/11/16 12:47 PMCardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13 - [at noodls] - Vancouver, Canada, May 11, 2016 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the first quarter ended March 31, 2016 on the morning of Friday, ...
05/11/16 12:47 PMCardiome Announces Publication of Spanish Emergency Department BRINAVESS Study - [at noodls] - Vancouver, Canada, May 11, 2016 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the publication of results from an open label, single-center, single-arm study conducted by independent ...

Social

About Cardiome Pharma Corp.

Cardiome Pharma Corp. logoCardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CRME
  • CUSIP:
Key Metrics:
  • Previous Close: $3.13
  • 50 Day Moving Average: $4.90
  • 200 Day Moving Average: $4.94
  • P/E Ratio: N/A
  • P/E Growth: -0.18
  • Market Cap: $63.71M
  • Beta: 1.22
  • Current Year EPS Consensus Estimate: $-0.63 EPS
  • Next Year EPS Consensus Estimate: $-0.34 EPS
Additional Links:
Cardiome Pharma Corp. (NASDAQ:CRME) Chart for Friday, July, 29, 2016